| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case of invasive mucinous adenocarcinoma of the lung showing stepwise progression at the primary site
|
Kawai, Hitomi
|
|
2019
|
136 |
C |
p. 94-97
|
artikel
|
| 2 |
A case of primary lung squamous cell carcinoma mimicking malignant mesothelioma producing granulocyte colony stimulating factor with chemotherapy (cisplatin and gemcitabine)-associated thrombotic thrombocytopenic purpura (TTP); An autopsy case report
|
Suzuki, Yasuhito
|
|
2019
|
136 |
C |
p. 105-108
|
artikel
|
| 3 |
An open-label phase IB study to evaluate GSK3052230 in combination with paclitaxel and carboplatin, or docetaxel, in FGFR1-amplified non-small cell lung cancer
|
Morgensztern, Daniel
|
|
2019
|
136 |
C |
p. 74-79
|
artikel
|
| 4 |
A phase II study of nab-paclitaxel and carboplatin chemotherapy plus necitumumab in the first-line treatment of patients with stage IV squamous non-small cell lung cancer
|
Villaruz, Liza C.
|
|
2019
|
136 |
C |
p. 52-56
|
artikel
|
| 5 |
A phase II study of pembrolizumab and paclitaxel in patients with relapsed or refractory small-cell lung cancer
|
Kim, Yu-Jung
|
|
2019
|
136 |
C |
p. 122-128
|
artikel
|
| 6 |
Brigatinib in patients with ALK-positive advanced non-small-cell lung cancer pretreated with sequential ALK inhibitors: A multicentric real-world study (BRIGALK study)
|
Descourt, Renaud
|
|
2019
|
136 |
C |
p. 109-114
|
artikel
|
| 7 |
Clinicopathologic features and lymph node metastatic characteristics in patients with adenocarcinoma manifesting as part-solid nodule exceeding 3 cm in diameter
|
Li, Wei
|
|
2019
|
136 |
C |
p. 37-44
|
artikel
|
| 8 |
Comment on: “Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos”
|
Barbone, Fabio
|
|
2019
|
136 |
C |
p. 150
|
artikel
|
| 9 |
Comment on: "Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos"
|
Harris, Edward J.A.
|
|
2019
|
136 |
C |
p. 148-149
|
artikel
|
| 10 |
Contents
|
|
|
2019
|
136 |
C |
p. v-vii
|
artikel
|
| 11 |
Correlation between maximum standardized uptake values on FDG-PET and microenvironmental factors in patients with clinical stage IA radiologic pure-solid lung adenocarcinoma
|
Ichikawa, Tomohiro
|
|
2019
|
136 |
C |
p. 57-64
|
artikel
|
| 12 |
Corrigendum to “Outcomes of patients with disease recurrence after treatment for locally advanced non-small cell lung cancer detected by routine follow-up CT scans versus a symptom driven evaluation” [Lung Cancer 135 (September) (2019) 16–20]
|
Bodor, J. Nicholas
|
|
2019
|
136 |
C |
p. 157
|
artikel
|
| 13 |
Corrigendum to “Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials” [Lung Cancer 120 (June) (2018) 137–141]
|
Maymani, Hossein
|
|
2019
|
136 |
C |
p. 158
|
artikel
|
| 14 |
Corrigendum to “Predicting pathologic response to neoadjuvant chemoradiation in resectable stage III non-small cell lung cancer patients using computed tomography radiomic features” [Lung Cancer 135 (September) (2019) 1–9]
|
Khorrami, Mohammadhadi
|
|
2019
|
136 |
C |
p. 156
|
artikel
|
| 15 |
Cost-effectiveness analysis of pembrolizumab monotherapy and chemotherapy in the non-small-cell lung cancer with different PD-L1 tumor proportion scores
|
Zhou, Kexun
|
|
2019
|
136 |
C |
p. 98-101
|
artikel
|
| 16 |
Current management of limited-stage SCLC and CONVERT trial impact: Results of the EORTC Lung Cancer Group survey
|
Levy, Antonin
|
|
2019
|
136 |
C |
p. 145-147
|
artikel
|
| 17 |
Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients
|
Song, Zhengbo
|
|
2019
|
136 |
C |
p. 23-29
|
artikel
|
| 18 |
Diminishing microbiome richness and distinction in the lower respiratory tract of lung cancer patients: A multiple comparative study design with independent validation
|
Jin, Jing
|
|
2019
|
136 |
C |
p. 129-135
|
artikel
|
| 19 |
Dynamic changes in PD-L1 expression and CD8+ T cell infiltration in non-small cell lung cancer following chemoradiation therapy
|
Choe, Eun-Ah
|
|
2019
|
136 |
C |
p. 30-36
|
artikel
|
| 20 |
Editorial Board
|
|
|
2019
|
136 |
C |
p. iii
|
artikel
|
| 21 |
EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations
|
Tang, Wenjie
|
|
2019
|
136 |
C |
p. 6-14
|
artikel
|
| 22 |
EGFR-TKI acquired resistance in lung cancers harboring EGFR mutations in immunocompetent C57BL/6J mice
|
Higo, Hisao
|
|
2019
|
136 |
C |
p. 86-93
|
artikel
|
| 23 |
Erratum to “High expression level of SOX2 is significantly associated with shorter survival in patients with thymic epithelial tumors” [Lung Cancer 132 (June) (2019) 9–16]
|
Lee, Guk Jin
|
|
2019
|
136 |
C |
p. 160
|
artikel
|
| 24 |
Erratum to “Intracerebral efficacy and tolerance of nivolumab in non–small-cell lung cancer patients with brain metastases” [Lung Cancer 116 (February 2018) 62–66]
|
Gauvain, Clément
|
|
2019
|
136 |
C |
p. 159
|
artikel
|
| 25 |
Erratum to “The metastatic site does not influence PD-L1 expression in advanced non-small cell lung carcinoma” [Lung Cancer 132 (June) (2019) 36–38]
|
Wang, H.
|
|
2019
|
136 |
C |
p. 161
|
artikel
|
| 26 |
Galectin-9 in non-small cell lung cancer
|
He, Yayi
|
|
2019
|
136 |
C |
p. 80-85
|
artikel
|
| 27 |
Increased risk of coronary heart disease and stroke in lung cancer survivors: A Korean nationwide study of 20,458 patients
|
Yoon, Dong Woog
|
|
2019
|
136 |
C |
p. 115-121
|
artikel
|
| 28 |
Molecular testing for advanced non-small cell lung cancer in Malaysia: Consensus statement from the College of Pathologists, Academy of Medicine Malaysia, the Malaysian Thoracic Society, and the Malaysian Oncological Society
|
Rajadurai, Pathmanathan
|
|
2019
|
136 |
C |
p. 65-73
|
artikel
|
| 29 |
PD-L1 expression on tumor-infiltrating immune cells is highly associated with M2 TAM and aggressive malignant potential in patients with resected non-small cell lung cancer
|
Sumitomo, Ryota
|
|
2019
|
136 |
C |
p. 136-144
|
artikel
|
| 30 |
PD-L1 testing on the EBUS-FNA cytology specimens of non-small cell lung cancer
|
Wang, Gang
|
|
2019
|
136 |
C |
p. 1-5
|
artikel
|
| 31 |
Performance of community-based lung cancer screening program in a Histoplasma endemic region
|
Bhandari, Shruti
|
|
2019
|
136 |
C |
p. 102-104
|
artikel
|
| 32 |
Pretreatment prognostic nutritional index as a novel biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors
|
Shoji, Fumihiro
|
|
2019
|
136 |
C |
p. 45-51
|
artikel
|
| 33 |
Primary resistance to icotinib in a patient with lung adenocarcinoma harboring EGFR L858R and Q787k mutations
|
Heng, Wei
|
|
2019
|
136 |
C |
p. 153-155
|
artikel
|
| 34 |
Response to comment on: “Low-dose computed tomography screening for lung cancer in people with workplace exposure to asbestos”
|
Maisonneuve, Patrick
|
|
2019
|
136 |
C |
p. 151-152
|
artikel
|
| 35 |
The clinical impact of family history of cancer in female never-smoker lung adenocarcinoma
|
Lee, Youngjoo
|
|
2019
|
136 |
C |
p. 15-22
|
artikel
|
Tijdschrift beschrijving